Sergliflozin etabonate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sergliflozin etabonate
Sergliflozin etabonate 2.svg
Clinical data
Routes of
administration
Oral
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
Formula C23H28O9
Molar mass 448.463 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Sergliflozin etabonate (INN/USAN,[1][2] codenamed GW869682X) is an investigational anti-diabetic drug being developed by GlaxoSmithKline. It did not undergo further development after phase II.[citation needed]

Method of action[edit]

Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[3][4]

Chemistry[edit]

Etabonate refers to the ethyl carbonate group. The remaining structure, which is the active substance, is called sergliflozin.

Sergliflozin

References[edit]